HIGHLIGHTS
- who: Andrew Vaillant from the Replicor Inc have published the article: Targeting Subviral Particles: A Critical Step in Achieving HBV Functional Cure but Where Are We with Current Agents in Clinical Development?, in the Journal: Viruses 2022, 14, 1193. of 30/05/2022
SUMMARY
The recent review by Drs. Moini and Fung on HBsAg loss as an important treatment endpoint for functional cure provides a good overview of the different compounds in development for the treatment of chronic HBV. ALG-010133 is a nucleic_acid polymer (NAP) that was under development by Aligos Therapeutics . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.